To amend the Federal Food, Drug, and Cosmetic Act with respect to postapproval study requirements for certain controlled substances, and for other purposes.
Long-Term Opioid Efficacy Act of 2018
This bill expands the authority of the Food and Drug Administration (FDA) to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
Became Public Law No: 115-271.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by Voice Vote.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5243-5244)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5811.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5243)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5243)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line